相似文献
1
Prognostic benefit of TILs independent of clinicopathological and molecular factors.肿瘤浸润淋巴细胞（TILs）的预后益处独立于临床病理和分子因素。
Br J Cancer. 2023 Sep;129(5):737-738. doi: 10.1038/s41416-023-02335-6. Epub 2023 Jul 13.
2
PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.肿瘤浸润淋巴细胞中的 PD-L1 表达是原发性肢端黑色素瘤患者的预后不良因素。
Histopathology. 2018 Sep;73(3):386-396. doi: 10.1111/his.13527. Epub 2018 Jun 8.
3
Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.PD-L1 和 TET1 表达与非小细胞肺癌肿瘤浸润淋巴细胞的临床病理相关性。
Pathol Res Pract. 2020 Nov;216(11):153188. doi: 10.1016/j.prp.2020.153188. Epub 2020 Aug 27.
4
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.谷氨酰胺酶表达是肿瘤浸润淋巴细胞水平高的淋巴结阳性三阴性乳腺癌患者的不良预后因素。
Virchows Arch. 2017 Apr;470(4):381-389. doi: 10.1007/s00428-017-2083-5. Epub 2017 Feb 9.
5
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.肿瘤浸润淋巴细胞（TILs）是国际乳腺癌研究组（IBCSG）III期随机临床试验22-00中三阴性乳腺癌患者的一个有力预后标志物。
Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2.
6
Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.为什么病理学家和肿瘤学家应该了解三阴性乳腺癌中的肿瘤浸润淋巴细胞（TILs）：来自澳大利亚的 139 例经验。
Pathology. 2020 Aug;52(5):515-521. doi: 10.1016/j.pathol.2020.04.004. Epub 2020 Jun 14.
7
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.新辅助化疗治疗的胰腺导管腺癌患者中肿瘤浸润淋巴细胞的预后意义
Pancreas. 2017 Oct;46(9):1180-1187. doi: 10.1097/MPA.0000000000000914.
8
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.评估切除的非小细胞肺癌中的肿瘤浸润淋巴细胞、吲哚胺 2,3-双加氧酶-1 和 PD-L1：具有临床病理和预后意义的免疫组织化学研究。
Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.
9
Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery.247 例手术后局限期小细胞肺癌的临床病理特征及预后分析。
Hum Pathol. 2021 Feb;108:84-92. doi: 10.1016/j.humpath.2020.11.007. Epub 2020 Nov 25.
10
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.三阴性乳腺癌中肿瘤浸润淋巴细胞的预后价值：一项荟萃分析。
Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1.
引用本文的文献
1
Prognostic and recurrence risk predictive values of tumor infiltrating lymphocytes in HER2-low breast cancer.HER2低表达乳腺癌中肿瘤浸润淋巴细胞的预后及复发风险预测价值
Clin Transl Oncol. 2025 Apr 27. doi: 10.1007/s12094-025-03921-1.
2
Role of Ultrasonographic and Clinicopathological Characteristics in Assessing Stromal Tumor-Infiltrating Lymphocyte Density in Triple-Negative Breast Cancer.超声及临床病理特征在评估三阴性乳腺癌间质肿瘤浸润淋巴细胞密度中的作用。
Balkan Med J. 2024 Oct 31;41(6):469-475. doi: 10.4274/balkanmedj.galenos.2024.2024-7-26. Epub 2024 Sep 26.
3
Immunotherapy for colorectal cancer.结直肠癌的免疫治疗。
Front Immunol. 2024 Aug 21;15:1433315. doi: 10.3389/fimmu.2024.1433315. eCollection 2024.
本文引用的文献
1
Can TILs supplement the TNM staging system (as TNM-Immune)?肿瘤浸润淋巴细胞（TILs）能否补充TNM分期系统（作为TNM免疫分期）？
Br J Cancer. 2023 Sep;129(5):739-740. doi: 10.1038/s41416-023-02368-x. Epub 2023 Jul 28.
2
Tumour-infiltrating lymphocytes: from prognosis to treatment selection.肿瘤浸润淋巴细胞：从预后到治疗选择。
Br J Cancer. 2023 Feb;128(3):451-458. doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23.
3
Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.三级淋巴结构对子宫内膜癌患者的预后至关重要。
Nat Commun. 2022 Mar 16;13(1):1373. doi: 10.1038/s41467-022-29040-x.
4
Multicentre Investigation of Prognostic Factors Incorporating p16 and Tumour Infiltrating Lymphocytes for Anal Cancer After Chemoradiotherapy.多中心研究：放化疗后分析癌症预后因素，包括 p16 和肿瘤浸润淋巴细胞。
Clin Oncol (R Coll Radiol). 2021 Oct;33(10):638-649. doi: 10.1016/j.clon.2021.04.015. Epub 2021 May 21.
5
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer.早期子宫内膜癌预后综合影像免疫及分子特征分析
Cancer Immunol Res. 2020 Dec;8(12):1508-1519. doi: 10.1158/2326-6066.CIR-20-0149. Epub 2020 Sep 30.
6
Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.三阴性乳腺癌中p53表达与肿瘤浸润淋巴细胞数量的相关性
J Pathol Transl Med. 2019 May;53(3):180-187. doi: 10.4132/jptm.2019.02.08. Epub 2019 Mar 11.
7
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.肿瘤浸润淋巴细胞预测 HPV 阳性口咽癌的预后。
Br J Cancer. 2014 Jan 21;110(2):489-500. doi: 10.1038/bjc.2013.639. Epub 2013 Oct 29.
8
Integrated genomic characterization of endometrial carcinoma.子宫内膜癌的综合基因组特征分析。
Nature. 2013 May 2;497(7447):67-73. doi: 10.1038/nature12113.
Zotero 插件